QUALITOP

Newsletter #1

We hope you are all safe and in good health!

Welcome to our newsletter and let us present you the project. To forward this newsletter, make sure to use this link. If someone forwarded you this newsletter do not forget to subscribe.

QUALITOP Project: Better monitoring of cancer immunotherapy patients



Follow @h2020qualitop on Facebook

QUALITOP project will provide a better monitoring of cancer immunotherapy patients using big data, artificial intelligence & simulation modelling approaches.

The main aim of this project is to develop a European immunotherapy-specific open Smart Digital Platform for personalized prevention and patient

management. The use of big data analysis, artificial intelligence and simulation modelling approaches will enable collecting efficiently real-world data to monitor health status and the quality of life of cancer patients given immunotherapy.

The project, which is part of the Horizon 2020 Research and Innovation Programme, will have a duration of 4 years (2020-2024).

Although cancer immunotherapy has significantly helped to advance in the field of cancer treatment, some challenges remain. To address this problems, the EU-funded QUALITOP platform will:

- Provide information about the patients' health status
- Define patient profiles in a real-world context
- Provide real-time recommendations

Follow @h2020qualitop on Twitter



European research project improving the quality of life of cancer patients undergoing immunotherapy

Several clinical centres from different EU member states together with the coordination of Hospices Civils de Lyon (France) will collect the specific data in regard to lifestyle, genetic, and psychosocial determinants of quality of life. Thus, QUALITOP will enable a better monitoring of the health and quality of life the cancer patients who are receiving immunotherapy.

Check our website!

Our mailing address is:
contact@qualitop-project.eu

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 875171.